Reported Sunday, Arrowhead Pharmaceuticals Announces New Phase 2 Data Of Plozasiran Published In JAMA Cardiology And Presented At ACC.24
Reported Sunday, Arrowhead Pharmaceuticals Announces New Phase 2 Data Of Plozasiran Published In JAMA Cardiology And Presented At ACC.24
據週日報道，Arrowhead Pharmicals宣佈了Plozasiran的新二期數據，該數據發表在《JAMA心臟病學》上，並在ACC.24上公佈
- - Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
- - SHASTA-3 and SHASTA-4 Phase 3 studies to be initiated
- -Plozasiran 將嚴重高甘油三酯血癥患者的甘油三酯和 APOC3 分別降低至 86% 和 90% 的平均最大值
- -SHASTA-3 和 SHASTA-4 三期研究即將啓動
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。